European Pharmaceutical Review

SEPTEMBER 14, 2023

Ultimately, this puts European businesses at a competitive disadvantage compared to other companies worldwide. Once adopted by the Council, the regulatory proposals are planned to come into force on 1 July 2028 (for BEFIT) and on 1 January 2026 (for the transfer pricing proposal).

Competition 97

Competition Pharma Pharmaceutical 97

Pharmaceutical Technology

MAY 19, 2023

However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. However, there is also competition with subcutaneous branded rituximab, which cannibalises Rituxan and complicates this assumption.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2% Sanofi and Regeneron’s market capitalisation grew by 12.4%

Marketing 52

Marketing Sales Pharma Leads 52

European Pharmaceutical Review

AUGUST 21, 2023

billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. This is mainly due to the reported decline in sales of Humira, a consequence of biosimilar competition. With the company’s monoclonal antibody drug candidate PRA023 predicted to reach $2.1

Biopharma 98

Biopharma Marketing Sales Medicine 98

pharmaphorum

AUGUST 4, 2022

The deal comes as Amgen has been under pressure from competition to its big-selling arthritis therapy Enbrel (etanercept) and blood cell booster Epogen (epoetin alfa), and a patent expiry for psoriasis blockbuster Otezla (apremilast) in 2028.

Side effects 85

Side effects Sales Pharma Competition 85

pharmaphorum

AUGUST 2, 2022

Now, Roche has an opportunity to add ease of administration to the competitive profile of Tecentriq, reducing the time patients have to spend in clinics and potentially reducing the cost of treatment. Results from a trial in first-line NSCLC are due in early 2023.

Marketing 102

Marketing Competition Patients FDA 102

PM360

SEPTEMBER 21, 2023

They do not have biosimilar or generic competition available in the market. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list. They do not qualify for any exemption (e.g., for orphan products or plasma therapies).

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

pharmaphorum

OCTOBER 10, 2022

Keytruda is due to lose patent protection in around 2028, and the threat of generic competition to it and other top sellers like type 2 diabetes therapy Januvia (sitagliptin) gives it one of the steeper patent cliffs among to-tier pharma groups.

Sales 52

Sales FDA Pharma Competition 52

Clarivate

AUGUST 27, 2024

In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. ablation market and would have a total global market value of $3 billion.

Marketing 52

Marketing Competition FDA Electronics 52

PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Management 105

Management Manufacturing Sales Competition 105

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

OCTOBER 28, 2022

billion and $812 million in 2028. Competition in an increasingly heated market. Vaxcyte’s recent clinical success brings further competition into a sector, which is becoming increasingly heated. VAX-24 has forecasted sales of $21 million in the same year. Further plans in the making.

Training 64

Training Marketing Competition FDA 64

Pharmaceutical Technology

FEBRUARY 13, 2023

By this same virtue, PROTACs are able to degrade previously undruggable targets, which provides a major competitive advantage for this modality if shown to be true. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028.

Competition 59

Competition Safety Patients Pharmaceutical 59

Medico Reach

OCTOBER 17, 2022

million by 2028. The potential increase in industry competition could also spell trouble for some. Now, the demand for such equipment is on track to grow exponentially. For instance, experts estimate that the global disposable spinal instruments market will grow at a CAGR of 8.3%, reaching a valuation of $96.5

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Clarivate

MAY 31, 2023

Pharma M&A activity was muted in 2022, coming in at its lowest level since 2013 – something of a surprise, given the looming patent cliff and pharma’s past reliance on M&A and biopartnering as a quick fix for revenues lost to generics and biosimilars competition. Of the biggest spenders in 2022, Merck/MSD opened its wallet the widest.

Pharma 52

Pharma Biopharma Medicine Healthcare 52

Every Ancillary

MAY 14, 2021

Cons: Highly competitive with new options continually emerging. That being said, the clinical laboratory market is expected to see growth of nearly 40% by 2028. Pros: A growing market means a good chance for long-term success with each client. Mostly cash-pay, which means dependable, fast commissions. Opportunities: Liquid Amnion.

Medical sales 52

Medical sales Medical Sales Insurance 52

European Pharmaceutical Review

NOVEMBER 30, 2023

NEWS: Biopharma struggling to find talent with adequate digital skills Looking onward to 2028, the Skills report predicted that, out of a total 81 percent within the cell and gene therapy industry, roles will span support services, R&D and discovery, and bioprocessing.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

Medico Reach

OCTOBER 17, 2022

million by 2028. The potential increase in industry competition could also spell trouble for some. Now, the demand for such equipment is on track to grow exponentially. For instance, experts estimate that the global disposable spinal instruments market will grow at a CAGR of 8.3%, reaching a valuation of $96.5

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Sales Talent

FEBRUARY 7, 2020

It also means that employers face the most competitive, candidate-driven employment market in history. jobs by 2028 , there should be an even bigger shortfall between the number of open jobs and available workers. In sum, we expect sales hiring in 2020 to continue its torrid pace which means great times ahead for sales professionals.

Sales 52

Sales B2B Sales Recruitment Marketing 52

Spotio

APRIL 4, 2023

billion by 2028. That means competition is fierce, especially in high-growth locations. The industry grew by 2.7% annually from 2015 to 2020 and is expected to reach $32.14 But it’s not all rainbows and sunshine… There are currently 37,340 roofing companies in the United States , a 1.2% increase from last year.

Prospecting 52

Prospecting Sales pitches Sales Leads 52

European Pharmaceutical Review

FEBRUARY 7, 2023

However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU. of the MDR and Article 110.4 of the IVDR for medical devices and in vitro diagnostic medical devices (IVDs).

Medical 117

Medical Government Marketing Medicine 117

Clarivate

APRIL 18, 2024

Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. In 2019, UnitedHealth Group CEO David Wichmann indicated a plan to make Optum a $100B business by 2028, including by partnering with health systems for administrative services such as RCM and IT.

Retail 52

Retail Healthcare Healthcare Physicians 52

PM360

SEPTEMBER 28, 2022

Although the dynamics within each therapeutic area may vary, certain archetypes could influence competitive dynamics. In this type of class, selecting one product could materially disrupt competitive dynamics. Competitive and pricing dynamics will vary based on the nuances associated with each therapeutic area.

Government 97

Government Manufacturing Prescription Competition 97

Pharmaceutical Technology

APRIL 20, 2023

The district court had previously blocked Sandoz and Zydus from producing, selling, offering to sell, or importing generic versions of Otezla until February 2028. This is one of several patent infringement cases Amgen has pursued in recent years to stave competition. billion worth of the drug worldwide. Patent No.

Competition 52

Competition Marketing FDA Prospecting 52

Pharmaceutical Technology

JUNE 20, 2023

DICE currently has two oral IL-17 inhibitors in clinical development; DC-806 is in Phase II trials for plaque psoriasis treatment, and DC-856 is in a Phase I for psoriasis.Acquiring these treatments could pave the way for Lilly to enter the highly competitive psoriasis market , where AbbVie, Pfizer and Johnson & Johnson have already clashed.

Prospecting 52

Prospecting Competition Biopharma Marketing 52

Pharmaceutical Technology

JUNE 16, 2023

As it stands, GlobalData analysis predicts that Keytruda’s yearly revenue will hit almost $35bn in 2028, up from $21bn in 2022. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

Food and Drug Administration 52

Food and Drug Administration FDA Prospecting Food 52

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics). In highly competitive categories like diabetes, net price could be half of the list price.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52